Charles Albright
Chief Tech/Sci/R&D Officer chez Affinia Therapeutics, Inc.
Profil
Charles Albright is currently the Chief Scientific Officer at Affinia Therapeutics, Inc. He previously worked as the VP-Genetically Defined Diseases & Genomics at Bristol Myers Squibb Co. from 2004 to 2016.
He also served as the Chief Scientific Officer & Executive VP at Editas Medicine, Inc. from 2016 to 2021.
Albright was an Assistant Professor at Vanderbilt University.
Albright received his undergraduate and doctorate degrees from Massachusetts Institute of Technology.
Postes actifs de Charles Albright
| Sociétés | Poste | Début |
|---|---|---|
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 01/01/2021 |
Anciens postes connus de Charles Albright
| Sociétés | Poste | Fin |
|---|---|---|
| EDITAS MEDICINE, INC. | Chief Tech/Sci/R&D Officer | 15/01/2021 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/08/2016 |
| Vanderbilt University | Corporate Officer/Principal | - |
Formation de Charles Albright
| Massachusetts Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| EDITAS MEDICINE, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
